AFT upgrades guidance following maiden US sale

AFT upgrades guidance following maiden US sale
Managing director Hartley Atkinson says he's confident AFT's investments will reward shareholders over the medium to long term. (Image: Supplied)
John Anthony
Dual-listed pharmaceutical company AFT Pharmaceuticals has lifted its profit guidance for the year to March following the first sale of its intravenous pain-relief medicine in the United States.AFT expects operating profit to range between $23 million and $25m, up on earlier guidance of $22m to $24m.US successIn a statement to the Australian securities exchange (ASX) and New Zealand stock exchange (NZX) on Friday morning, AFT said the update followed a review of January trading and news that Hikma Pharmaceuticals, the US licensee of its pain-re...

More Markets

Smyth to stay on as Spark chair for another year
Markets

Smyth to stay on as Spark chair for another year

The past year had been one of the toughest in Spark's history, chair says.

How NZ became a hotspot for mining stocks
Markets Small Cap Wrap

How NZ became a hotspot for mining stocks

Extractive industry haters look away – NZ mining firms are having a moment.

Ryman, Fletcher lift as market ends 9-day winning streak
Markets

Ryman, Fletcher lift as market ends 9-day winning streak

Market down despite Fletcher Building and Ryman Healthcare rising.

Tom Raynel 06 Nov 2025